Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players

News provided by

Reportlinker

16 Apr, 2013, 04:03 ET

NEW YORK, April 16, 2013 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players
http://www.reportlinker.com/p01160237/Oncology-Therapeutics-Market-in-India-to-2018---Introduction-of-Market-Based-Pricing-to-Fuel-Price-Wars-and-Intense-Competition-Among-Domestic-and-Multinational-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy


Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players


Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players", which provides in-depth analysis of the key therapeutic indications of oncology, breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin's Lymphoma (NHL), with forecasts until 2018. It also looks at treatment usage patterns and includes insights into the oncology R&D pipeline.


The Indian oncology therapeutics market for breast cancer, lung cancer, colorectal cancer, prostate cancer and NHL was estimated to be worth $153.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 12.7% from 2004. It is expected to reach $238.8m in 2018 at a CAGR of 6.5% from 2011. The slower growth in the forecast period is mainly due to the reduction in the price of leading marketed products for breast cancer, colorectal cancer, lung cancer and NHL after all 348 drugs on the National List of Essential Medicines (NLEM) are brought under price control regulations.


The limitations of the current market are unclear patent laws, restrictive pricing and reimbursement policies, ailing infrastructure, and insufficient government aid. Low patient affordability is also a major restraint, and one that reimbursement and insurance policies must address if the market is to develop in the future.


Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the breast cancer, colorectal cancer, prostate cancer, lung cancer and NHL markets.
- Data and analysis for the oncology therapeutics market in India
- Annualized market data for the oncology therapeutics market in India from 2004 to 2011, with forecasts to 2018
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the oncology therapeutics market in India
- Key M&A activities and licensing agreements that have taken place in the Indian oncology therapeutics market


Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to the markets with high growth potential
- Develop market-entry and market-expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the oncology market
- Develop key strategic initiatives by understanding the key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships



Table of Contents

1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 10
2 Oncology Therapeutics Market in India – Introduction 11
3 Oncology Therapeutics Market in India – Market Overview 12
3.1 Population Dynamics 12
3.2 Cancer Registration Background in India 13
3.3 Most Common Cancers in India 14
3.4 Cancer Mortality Rate 15
3.5 Market Characterization and Forecasts 16
3.6 Annual Cost of Therapy 18
3.7 Treatment Usage Pattern 19
3.7.1 Diseased Population 20
3.7.2 Prescription Population 20
3.8 Drivers and Barriers 21
3.8.1 Drivers 21
3.8.2 Restraints 22
4 Oncology Therapeutics Market in India – Therapeutic Landscape 24
4.1 Breast Cancer 24
4.1.1 Disease Overview 24
4.1.2 Staging 24
4.1.3 Market Size 26
4.1.4 Annual Cost of Therapy 28
4.1.5 Treatment Usage Pattern 29
4.1.6 Key Marketed Products 30
4.1.7 Competitive Landscape 31
4.2 Colorectal Cancer 32
4.2.1 Disease Overview 32
4.2.2 Staging 32
4.2.3 Market Size 34
4.2.4 Annual Cost of Therapy 35
4.2.5 Treatment Usage Pattern 36
4.2.6 Key Marketed Products 37
4.2.7 Competitive Landscape 38
4.3 Prostate Cancer 39
4.3.1 Disease Overview 39
4.3.2 Staging 39
4.3.3 Market Size 41
4.3.4 Annual Cost of Therapy 42
4.3.5 Treatment Usage Pattern 43
4.3.6 Key Marketed Products 44
4.3.7 Competitive Landscape 45
4.4 Lung Cancer 46
4.4.1 Disease Overview 46
4.4.2 Staging 46
4.4.3 Market Size 49
4.4.4 Annual Cost of Therapy 50
4.4.5 Treatment Usage Pattern 51
4.4.6 Key Marketed Products 52
4.4.7 Competitive Landscape 53
4.5 Non-Hodgkin's Lymphoma 54
4.5.1 Disease Overview 54
4.5.2 Staging 54
4.5.3 Market Size 55
4.5.4 Annual Cost of Therapy 56
4.5.5 Treatment Usage Pattern 57
4.5.6 Key Marketed Products 58
4.5.7 Competitive Landscape 59
5 Oncology Therapeutics Market in India – Pipeline Analysis 60
5.1 Introduction 60
5.2 Breast Cancer 61
5.2.1 Introduction 61
5.3 Colorectal Cancer 64
5.3.1 Introduction 64
5.4 Prostate Cancer 66
5.4.1 Introduction 66
5.5 Lung Cancer 68
5.5.1 Introduction 68
5.6 Non-Hodgkin's Lymphoma 71
5.6.1 Introduction 71
6 Oncology Therapeutics Market in India – Competitive Landscape 73
6.1 Market Share Analysis 73
6.2 Competitive Profiling 74
6.2.2 Dr. Reddy's Laboratories 75
6.2.3 Natco Pharma 76
6.2.4 AstraZeneca 77
6.2.5 Cipla 78
7 Oncology Therapeutics Market in India – Strategic Consolidations 79
7.1 Introduction 79
7.2 Merger & Acquisition Deals 80
7.2.1 M&A by Year 80
7.3 Licensing Agreements 82
7.3.1 Deals by Year 82
7.3.2 Major Licensing Deals 82
7.4 Co-Development Deals 84
7.4.1 Deals by Year 84
7.4.2 Major Co-Development Deals 84
8 Oncology Therapeutics Market in India – Appendix 85
8.1 Market Definitions 85
8.2 Abbreviations 85
8.3 Bibliography 86
8.4 Research Methodology 86
8.4.1 Coverage 86
8.4.2 Secondary Research 87
8.4.3 Primary Research 87
8.4.4 Expert Panel Validation 88
8.5 Contact Us 88
8.6 Disclaimer 88



List of Tables

Table 1: Oncology Therapeutics Market, India, Incidence and Prevalence by Cancer Type, 2008 14
Table 2: Oncology Therapeutics Market, India, Estimated Cancer Deaths by Cancer Type, 2010 15
Table 3: Oncology Therapeutics Market, India, Revenue ($m), 2004–2011 17
Table 4: Oncology Therapeutics Market, India, Revenue Forecast ($m), 2011–2018 17
Table 5: Oncology Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011 18
Table 6: Oncology Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018 18
Table 7: Oncology Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2011 19
Table 8: Oncology Therapeutics Market, India, Treatment Usage Pattern ('000), 2011–2018 19
Table 9: Breast Cancer Therapeutics Market, India, Staging Description, 2012 24
Table 10: Breast Cancer Therapeutics Market, India, Staging Grouping, 2012 25
Table 11: Breast Cancer Therapeutics Market, India, Revenue ($m), 2004–2011 27
Table 12: Breast Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018 27
Table 13: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011 28
Table 14: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018 28
Table 15: Breast Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2011 29
Table 16: Breast Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2011–2018 30
Table 17: Breast Cancer Therapeutics Market, India, Key Marketed Products, 2011 30
Table 18: Colorectal Cancer Therapeutics Market, India, Staging Description, 2012 32
Table 19: Colorectal Cancer Therapeutics Market, India, Staging Grouping, 2012 33
Table 20: Colorectal Cancer Therapeutics Market, India, Revenue ($m), 2004–2011 34
Table 21: Colorectal Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018 34
Table 22: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011 35
Table 23: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018 35
Table 24: Colorectal Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2011 37
Table 25: Colorectal Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2011–2018 37
Table 26: Colorectal Cancer Therapeutics Market, India, Key Marketed Products, 2011 37
Table 27: Prostate Cancer Therapeutics Market, India, Staging Description, 2012 39
Table 28: Prostate Cancer Therapeutics Market, India, Staging Grouping, 2012 40
Table 29: Prostate Cancer Therapeutics Market, India, Revenue ($m), 2004–2011 41
Table 30: Prostate Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018 41
Table 31: Prostate Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011 42
Table 32: Prostate Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018 42
Table 33: Prostate Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2011 44
Table 34: Prostate Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2011–2018 44
Table 35: Prostate Cancer Therapeutics Market, India, Key Marketed Products, 2011 44
Table 36: Lung Cancer Therapeutics Market, India, Staging Description, 2012 46
Table 37: Lung Cancer Therapeutics Market, India, Staging Grouping, 2012 48
Table 38: Lung Cancer Therapeutics Market, India, Revenue ($m), 2004–2011 49
Table 39: Lung Cancer Therapeutics Market, India, Revenue Forecast ($m), 2011–2018 49
Table 40: Lung Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011 50
Table 41: Lung Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018 50
Table 42: Lung Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2011 52
Table 43: Lung Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2011–2018 52
Table 44: Lung Cancer Therapeutics Market, India, Key Marketed Products, 2011 52
Table 45: Non-Hodgkin's Lymphoma Therapeutics Market, India, Staging Description, 2012 54
Table 46: Non-Hodgkin's Lymphoma Therapeutics Market in India, Revenue ($m), 2004–2011 55
Table 47: Non-Hodgkin's Lymphoma Therapeutics Market, India, Revenue Forecast ($m), 2011–2018 55
Table 48: Non-Hodgkin's Lymphoma Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2011 56
Table 49: Non-Hodgkin's Lymphoma Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2018 56
Table 50: Non-Hodgkin's Lymphoma Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2011 58
Table 51: Non-Hodgkin's Lymphoma Therapeutics Market, India, Treatment Usage Pattern ('000), 2011–2018 58
Table 52: Non-Hodgkin's Lymphoma Therapeutics Market, India, Key Marketed Products, 2011 58
Table 53: Oncology Therapeutics Market, India, Breast Cancer Pipeline by Phase, 2012 61
Table 54: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase I, 2012 62
Table 55: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase I/II, 2012 62
Table 56: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase II, 2012 62
Table 57: Oncology Therapeutics Market, India, Breast Cancer Pipeline, Phase III, 2012 63
Table 58: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline by Phase, 2012 64
Table 59: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase I/II, 2012 65
Table 60: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase II, 2012 65
Table 61: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase II/III, 2012 65
Table 62: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline, Phase III, 2012 65
Table 63: Oncology Therapeutics Market, India, Prostate Cancer Pipeline by Phase, 2012 66
Table 64: Oncology Therapeutics Market, India, Prostate Cancer Pipeline, Phase II, 2012 66
Table 65: Oncology Therapeutics Market, India, Prostate Cancer Pipeline, Phase III, 2012 67
Table 66: Oncology Therapeutics Market, India, Lung Cancer Pipeline by Phase, 2012 68
Table 67: Oncology Therapeutics Market, India, Lung Cancer Pipeline, Phase I/II, 2012 68
Table 68: Oncology Therapeutics Market, India, Lung Cancer Pipeline, Phase II, 2012 69
Table 69: Oncology Therapeutics Market, India, Lung Cancer Pipeline, Phase III, 2012 70
Table 70: Oncology Therapeutics Market, India, Non-Hodgkin's Lymphoma Pipeline by Phase, 2012 71
Table 71: Oncology Therapeutics Market, India, Non-Hodgkin's Lymphoma Pipeline, Phase II/III, 2012 71
Table 72: Oncology Therapeutics Market, India, Non-Hodgkin's Lymphoma Pipeline, Phase III, 2012 72



List of Figures

Figure 1: Oncology Therapeutics Market, India, Population Growth Forecast (million), 2001–2025 12
Figure 2: Oncology Therapeutics Market, India, Revenue Forecast ($m), 2004–2018 16
Figure 3: Oncology Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018 18
Figure 4: Oncology Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2018 19
Figure 5: Oncology Therapeutics Market, India, Key Drivers and Barriers, 2012 21
Figure 6: Breast Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018 26
Figure 7: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018 28
Figure 8: Breast Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2018 29
Figure 9: Breast Cancer Therapeutics Market, India, Top Manufacturers, Market Share, 2011 31
Figure 10: Colorectal Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018 34
Figure 11: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018 35
Figure 12: Colorectal Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2018 36
Figure 13: Colorectal Cancer Therapeutics Market, India, Top Manufacturers, Market Share, 2011 38
Figure 14: Prostate Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018 41
Figure 15: Prostate Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018 42
Figure 16: Prostate Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2018 43
Figure 17: Prostate Cancer Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011 45
Figure 18: Lung Cancer Therapeutics Market, India, Revenue Forecast ($m), 2004–2018 49
Figure 19: Lung Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018 50
Figure 20: Lung Cancer Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2018 51
Figure 21: Lung Cancer Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011 53
Figure 22: Non-Hodgkin's Lymphoma Therapeutics Market, India, Revenue Forecast ($m), 2004–2018 55
Figure 23: Non-Hodgkin's Lymphoma Therapeutics Market, India, Annual Cost of Therapy ($), 2004–2018 56
Figure 24: Non-Hodgkin's Lymphoma Therapeutics Market, India, Treatment Usage Pattern ('000), 2004–2018 57
Figure 25: Non-Hodgkin's Lymphoma Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011 59
Figure 26: Oncology Therapeutics Market, India, R&D Pipeline by Indication (%), 2012 60
Figure 27: Oncology Therapeutics Market, India, Breast Cancer Pipeline by Phase (%), 2012 61
Figure 28: Oncology Therapeutics Market, India, Colorectal Cancer Pipeline by Phase (%), 2012 64
Figure 29: Oncology Therapeutics Market, India, Prostate Cancer Pipeline by Phase (%), 2012 66
Figure 30: Oncology Therapeutics Market, India, Lung Cancer Pipeline by Phase (%), 2012 68
Figure 31: Oncology Therapeutics Market, India, Non-Hodgkin's Lymphoma Pipeline by Phase (%), 2012 71
Figure 32: Oncology Therapeutics Market, India, Top Manufacturers, Market Share (%), 2011 73
Figure 33: Oncology Therapeutics Market, India, Hoffmann-La Roche, SWOT Analysis, 2011 74
Figure 34: Oncology Therapeutics Market, India, Dr. Reddy's Laboratories, SWOT Analysis, 2011 75
Figure 35: Oncology Therapeutics Market, India, Natco Pharma, SWOT Analysis, 2011 76
Figure 36: Oncology Therapeutics Market, India, AstraZeneca, SWOT Analysis, 2011 77
Figure 37: Oncology Therapeutics Market, India, Cipla, SWOT Analysis, 2011 78
Figure 38: Oncology Therapeutics Market, India, Strategic Consolidation, Deals by Type, 2008–2012 79
Figure 39: Oncology Therapeutics Market, India, M&A by Year, 2008–2012 80
Figure 40: Oncology Therapeutics Market, India, Licensing Agreements by Year, 2008–2012 82
Figure 41: Oncology Therapeutics Market, India, Co-Development Deals by Year, 2008–2012 84



Companies Mentioned

Dr. Reddy's Laboratories
Natco Pharma
AstraZeneca
Cipla





To order this report:
Therapy Industry: Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players


 


Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.